Wegovy Maker Novo Nordisk’s Shares Slump After Guidance Disappoints

Core Viewpoint - Novo Nordisk's stock experienced a significant decline following a disappointing guidance for 2026, with shares dropping 19% in early European trading after a 15% decrease in New York [1][2]. Group 1: Financial Forecast - The company expects adjusted sales and operating profit to decline by 5% to 13% at constant exchange rates for the year, which is worse than market expectations of a 2.1% sales drop and a 3.6% decline in adjusted earnings [2]. - The disappointing forecast is attributed to increased pricing pressure due to a recent agreement with the U.S. government to lower obesity drug prices, which will expand patient access through government healthcare programs [3]. Group 2: Competitive Landscape - Novo Nordisk faces intense competition from Eli Lilly's weight-loss drug and is also dealing with imminent patent expirations for key ingredients in Ozempic and Wegovy in Canada, Brazil, and China [4]. - Despite the challenges, the company reported a strong launch of the Wegovy weight-loss pill, which has shown promising early uptake with over 170,000 prescriptions in the first four weeks [5]. Group 3: Market Dynamics - The company is contending with lower-cost versions of its Ozempic and Wegovy products produced by compounding pharmacies in the U.S., which were expected to cease distribution after the branded medicines were removed from the FDA shortage list [6]. - Fourth-quarter sales of Wegovy increased by 17% year-over-year, indicating some positive momentum despite the overall challenges [7].